These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32151708)

  • 1. Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane.
    Bahrami N; Chang G; Kanaya N; Sauer T; Park D; Loeng M; Gravdehaug B; Chen S; Geisler J
    J Steroid Biochem Mol Biol; 2020 Jun; 200():105641. PubMed ID: 32151708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
    Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NEOLETEXE trial: a neoadjuvant cross-over study exploring the lack of cross resistance between aromatase inhibitors.
    Bahrami N; Sauer T; Engebretsen S; Aljabri B; Bemanian V; Lindstrøm J; Lüders T; Kristensen V; Lorentzen A; Loeng M; Ødegård HP; Kvaløy JØ; Vestøl IB; Geisler SB; Gravdehaug B; Gundersen JM; Geisler J
    Future Oncol; 2019 Nov; 15(32):3675-3682. PubMed ID: 31513453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
    Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
    Chanplakorn N; Chanplakorn P; Suzuki T; Ono K; Chan MS; Miki Y; Saji S; Ueno T; Toi M; Sasano H
    Breast Cancer Res Treat; 2010 Apr; 120(3):639-48. PubMed ID: 20151319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
    Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
    Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer.
    Folkerd EJ; Dixon JM; Renshaw L; A'Hern RP; Dowsett M
    J Clin Oncol; 2012 Aug; 30(24):2977-80. PubMed ID: 22802308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'.
    Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Cufer T; Lobelle JP; Mattiaci MR; Piccart M; Paridaens R
    Ann Oncol; 2004 Feb; 15(2):211-7. PubMed ID: 14760111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin.
    Bahrami N; Jabeen S; Tahiri A; Sauer T; Ødegård HP; Geisler SB; Gravdehaug B; Reitsma LC; Selsås K; Kristensen V; Geisler J
    Breast Cancer Res Treat; 2021 Dec; 190(3):435-449. PubMed ID: 34554372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Changes in the Lipid Profiles of Eastern Chinese Postmenopausal Women With Early-Stage Breast Cancer Treated With Different Aromatase Inhibitors: A Retrospective Study.
    Tian W; Wu M; Deng Y
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):837-843. PubMed ID: 29287126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
    Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients.
    Carlini P; Michelotti A; Ferretti G; Ricci S; Giannarelli D; Pellegrini M; Cresti N; Di Cosimo S; Bria E; Papaldo P; Fabi A; Ruggeri EM; Milella M; Alimonti A; Salesi N; Cognetti F
    Cancer Invest; 2007 Mar; 25(2):102-5. PubMed ID: 17453821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
    Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
    J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.